KRTL Holding Group Inc. has acquired Neurogen Brain Balancing LLC, a California-based neurotechnology company. Known for its advanced brain balancing therapies and personalized cognitive optimization systems, Neurogen will now operate as a subsidiary of Lakewood-based KRTL Holding.
This acquisition expands KRTL’s footprint in the mental wellness sector and strengthens its position at the convergence of neuroscience, biotechnology and global health care. KRTL has acquired 100% of Neurogen’s equity through a stock-based structure, which includes a collaborative profit-sharing agreement. KRTL will also support Neurogen’s entry into new markets and enhance regulatory pathways.
“We are thrilled to welcome Neurogen into the KRTL Holding Group family,” said Cesar Herrera, CEO of KRTL Holding Group. “In today’s rapidly evolving global environment, diversification is not just a strategy — it’s a necessity. By bringing Neurogen into our ecosystem, we strengthen our ability to remain agile, resilient and forward-thinking across multiple sectors.”
Neurogen employs proprietary neurotechnology that utilizes neuromodulation protocols to enhance cognitive performance, reduce stress and aid recovery from trauma. The platform aims to fill critical gaps in care for patients seeking alternative therapies and provides non-opioid, non-invasive treatment options.
“This acquisition marks an exciting new chapter for Neurogen. Joining forces with KRTL Holding Group enables us to accelerate our mission of transforming mental health treatment through cutting-edge neurotechnology,” said Gregory Gillispie, president of NeuroGen. “Together, we aim to expand access to non-invasive, personalized brain health therapies — advancing a new global standard for neurological wellness.”
The integration of Neurogen into KRTL’s operational framework includes brand alignment, financial system harmonization and regulatory compliance efforts. KRTL’s Quality Management System and Enterprise Resource Planning infrastructure are under review to support joint business capabilities. Neurogen will also participate in real-world data research with Centro de Investigaciones Químicas – CIQ S.R.L in Bolivia.
KRTL plans to provide updates on the integration progress and future developments as the collaboration continues to evolve.
